Mind Games; Alberta Oil; and Going Postal
An Alzheimer’s drug brought to market in one of the most controversial FDA approval processes ever– is the subject of my cover story this week on Full Measure. Aducanumab, now sold as Aduhelm, was introduced last June at a cost of $50,000 a year per patient. The FDA approved it even though not one of […]
Continue reading Mind Games; Alberta Oil; and Going Postal on sharylattkisson.com.
